ESR1 and neoplasm: Across these three original studies, the prevalence of ER activating mutations was between 17.5 and 54% in metastatic samples, with the same mutations rarely identified in primary tumour samples, matched or otherwise (Merenbakh-Lamin et al. 2013, Robinson et al. 2013, Toy et al. 2013).